What is Leerink Partnrs’ Estimate for SAGE Q1 Earnings?

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Sage Therapeutics in a report released on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical company will post earnings of ($1.03) per share for the quarter. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($0.99) EPS and Q4 2025 earnings at ($0.98) EPS.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%.

Several other research analysts also recently weighed in on the company. Truist Financial cut their price target on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, October 30th. Piper Sandler cut their price target on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, January 2nd. Scotiabank cut their price target on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating for the company in a report on Wednesday. StockNews.com downgraded Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Finally, HC Wainwright reiterated a “neutral” rating and issued a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday. Three equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $9.65.

Sage Therapeutics Stock Performance

Shares of SAGE opened at $7.18 on Thursday. The stock has a fifty day moving average of $6.34 and a two-hundred day moving average of $6.93. The company has a market capitalization of $439.20 million, a PE ratio of -1.29 and a beta of 0.94. Sage Therapeutics has a fifty-two week low of $4.62 and a fifty-two week high of $27.39.

Institutional Trading of Sage Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP boosted its position in Sage Therapeutics by 2.0% in the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock valued at $40,372,000 after buying an additional 111,123 shares during the last quarter. State Street Corp boosted its position in Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after buying an additional 451,377 shares during the last quarter. Geode Capital Management LLC boosted its position in Sage Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,256,903 shares of the biopharmaceutical company’s stock valued at $6,827,000 after buying an additional 14,049 shares during the last quarter. Federated Hermes Inc. boosted its position in Sage Therapeutics by 63.7% in the 4th quarter. Federated Hermes Inc. now owns 1,105,779 shares of the biopharmaceutical company’s stock valued at $6,004,000 after buying an additional 430,432 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Sage Therapeutics by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company’s stock valued at $2,510,000 after buying an additional 10,116 shares during the last quarter. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.